+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 56 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are gathering real-world data from patients with Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase Ph-CML-CP who are treated with tyrosine kinase inhibitors TKIs approved for first or second line therapy. This registry study aims to collect evidence on the tolerability, safety, effectiveness, and patient-reported outcomes over a prospective follow-up period of 5 years to understand long-term treatment results in routine healthcare settings. Participants will be those receiving TKI treatments including asciminib, bosutinib, dasatinib, imatinib, or nilotinib as prescribed in standard medical care, either as initial therapy or after one prior TKI therapy. The study includes patients who began these treatments on or after specified dates and those continuing asciminib after participating in an interventional trial. There is no treatment allocation instead, patients are observed based on their current prescribed TKI therapy. During the 5-year follow-up, participants treatment continuation and discontinuation due to adverse events will be monitored, along with the occurrence of adverse events, treatment switches, molecular and hematological responses, survival outcomes, and patient-reported measures of health, symptoms, and medication adherence. Data will be collected from electronic medical records and claims data with patient consent, ensuring ongoing safety and effectiveness observations in real-world care up to 5 years.

Age: 18Years - 100YearsAll Genders
17 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
E

Actively Recruiting

Researchers are evaluating treatment adherence and patient-reported outcomes in females with Stage I-III estrogen receptor positive ER, human epidermal growth factor receptor 2 negative HER2- early breast cancer who are intolerant to prior aromatase inhibitor AI therapy. This Phase IIIb, single-arm study focuses on participants who have experienced intolerance to adjuvant AI therapy, aiming to understand the effects of switching to giredestrant as an alternative endocrine therapy. The study is sponsored by Genentech, Inc. Participants will receive giredestrant orally at a dose of 30 mg once daily in 28-day cycles for up to 4.5 years or until disease recurrence or unacceptable toxicity occurs. The study monitors how well participants tolerate giredestrant and their adherence to this treatment after switching from prior AI therapy. There is no placebo or comparison group as all participants receive giredestrant. Throughout the study, participants will be regularly assessed for treatment discontinuation rates, severity of adverse events, and improvements in endocrine therapy-specific symptoms, pain, physical and functional well-being, and overall quality of life using validated questionnaires. These assessments occur at baseline and at 6 and 12 months, with safety monitoring continuing up to 28 days after the final dose. Participants are followed for up to 4.5 years, providing extended observation of treatment effects and tolerability.

Age: 18Years +FEMALEPhase 3
8 locations
P

Actively Recruiting

Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.

Age: 18Years +All GendersPhase 3
277 locations
C

Actively Recruiting

Researchers are studying two surgical procedures to reduce the risk of ovarian cancer in women with BRCA1 genetic mutations. This trial compares bilateral salpingectomy, which removes only the fallopian tubes, with bilateral salpingo-oophorectomy, which removes both fallopian tubes and ovaries. The goal is to find out if removing just the fallopian tubes with delayed ovary removal is nearly as effective as removing both from the start. Participants choose between two groups one undergoes bilateral salpingectomy with the option of later ovary removal, and the other undergoes bilateral salpingo-oophorectomy. Both groups have imaging tests like pelvic ultrasounds or pelvic MRIs during screening and provide blood samples throughout the study. Follow-up visits occur at multiple time points, including 10 to 60 days, 6 months, 12 months, 24 months, and then yearly for up to 20 years. During the study, researchers track if ovarian or related cancers develop and assess symptoms related to estrogen loss, quality of life, cancer-related distress, sexual function, menopausal symptoms, medical decision making, and any adverse events. Various questionnaires and imaging tests support these evaluations. Long-term safety and cancer risk reduction are monitored for up to two decades after surgery.

Age: 35Years - 50YearsFEMALEPhase Not Applicable
574 locations
C

Actively Recruiting

This clinical trial investigates treatment options for men with unfavourable risk localized prostate cancer. Researchers are comparing a newer radiation method called Stereotactic Body Radiation Therapy SBRT, which uses higher doses over fewer sessions with special equipment, against the standard external beam radiation combined with a brachytherapy boost. The study aims to find out if SBRT is as effective as the standard approach in controlling prostate cancer progression. Participants will receive either the standard treatment involving external beam radiation to the pelvis and prostate plus a brachytherapy boost, combined with hormone therapy, or the experimental SBRT treatment delivering higher radiation doses in fewer sessions. Adjuvant androgen deprivation therapy ADT will be given according to risk level, lasting 6 months for intermediate risk and 24 months for high or very high risk. Treatments are assigned randomly to compare outcomes between groups. Throughout the study, participants will be monitored for cancer progression, side effects, and quality of life using questionnaires and medical assessments for up to 8.6 years. Researchers will track progression-free survival, PSA response, metastasis-free survival, and overall survival, as well as participant-reported tolerability and economic outcomes. Safety will be assessed continuously to understand how well participants tolerate the treatments over time.

Age: 18Years +MALEPhase 3
57 locations
E

Actively Recruiting

Healthy Volunteer

This trial investigates the effects of aromatherapy on preoperative anxiety, postoperative pain, and overall patient experience in adults undergoing surgery under general anesthesia. It aims to explore how adding aromatherapy to standard care might influence these outcomes, addressing concerns about opioid use for pain management and improving comfort during the perioperative period. The study is a randomized control clinical trial conducted at Kaiser Stockton Ambulatory Surgery Unit. Participants are randomly assigned to receive either a scented aromatherapy pod containing a blend of Lavender and Sweet Orange or an unscented pod that serves as a placebo. Aromatherapy is applied before surgery to assess its impact on anxiety and pain levels. The study spans 18 months with assessments conducted before surgery, during recovery in the Post-Anesthesia Care Unit, and follow-up evaluations conducted two weeks after discharge to capture patient experience. During the study, participants anxiety is measured using the Preoperative Anxiety Scale-7 at multiple points on the day of surgery. Postoperative pain is evaluated both verbally and non-verbally at regular intervals from preoperative baseline through discharge. Patient experience is assessed via a questionnaire one week after surgery via a phone call. The trial collects detailed data on anxiety, pain, and satisfaction to analyze the effects of aromatherapy compared to standard care, with safety and adherence monitored throughout the trial period.

Age: 18Years +All GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.

Age: 18Years +All Genders
491 locations
B

Actively Recruiting

Researchers are evaluating the effectiveness of comprehensive molecular testing for patients with advanced cancers in community settings. The study focuses on breast cancer, non-small cell lung cancer, melanoma, and sarcoma. It aims to identify actionable genetic findings, assess feasibility and turnaround time of testing, and determine how often patients enroll in clinical trials based on the test results. The study uses the BostonGene Tumor Portrait test, a high-throughput sequencing platform that provides detailed genetic and molecular information about tumors and their environments. The research includes four groups of 100 patients each, categorized by cancer type. The study lasts up to two years, collecting data on demographics, medical history, treatment decisions, and patient outcomes. Participants will undergo genomic and molecular profiling with data gathered on test results, treatment plans, and patient progress. Researchers will measure how frequently actionable findings occur and the speed of test results. They will also observe how often patients receive therapies matched to their molecular profiles and track treatment decisions over time.

Age: 18Years +All Genders
7 locations
B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations

1-10 of 56

1